Business Description
PharmaEngine Inc
ISIN : TW0004162003
Total Employee Number:
45Description
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 124.51 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.07 | |||||
Interest Coverage | 1453.52 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 27.03 | |||||
Beneish M-Score | -0.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.6 | |||||
3-Year EBITDA Growth Rate | 8.9 | |||||
3-Year EPS without NRI Growth Rate | 6.6 | |||||
3-Year FCF Growth Rate | 105.7 | |||||
3-Year Book Growth Rate | 8.4 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.69 | |||||
9-Day RSI | 41.08 | |||||
14-Day RSI | 45.5 | |||||
3-1 Month Momentum % | 15.77 | |||||
12-1 Month Momentum % | -7.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 29.16 | |||||
Quick Ratio | 29.03 | |||||
Cash Ratio | 27.8 | |||||
Days Inventory | 181.98 | |||||
Days Sales Outstanding | 26.65 | |||||
Days Payable | 229.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 9.66 | |||||
Dividend Payout Ratio | 2.05 | |||||
3-Year Dividend Growth Rate | 30.5 | |||||
Forward Dividend Yield % | 3.22 | |||||
5-Year Yield-on-Cost % | 43.64 | |||||
Shareholder Yield % | 9.5 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.32 | |||||
Operating Margin % | 48.41 | |||||
Net Margin % | 43.84 | |||||
EBITDA Margin % | 58.4 | |||||
FCF Margin % | 18.52 | |||||
OCF Margin % | 18.52 | |||||
ROE % | 8.47 | |||||
ROA % | 7.82 | |||||
ROIC % | 273.43 | |||||
3-Year ROIIC % | 504.5 | |||||
ROC (Joel Greenblatt) % | 1812.87 | |||||
ROCE % | 11.04 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 21.19 | |||||
Forward PE Ratio | 16.52 | |||||
PE Ratio without NRI | 21.19 | |||||
Shiller PE Ratio | 14.8 | |||||
Price-to-Owner-Earnings | 20.12 | |||||
PEG Ratio | 3.42 | |||||
PS Ratio | 9.32 | |||||
PB Ratio | 1.76 | |||||
Price-to-Tangible-Book | 1.76 | |||||
Price-to-Free-Cash-Flow | 47.95 | |||||
Price-to-Operating-Cash-Flow | 47.95 | |||||
EV-to-EBIT | 7.22 | |||||
EV-to-Forward-EBIT | 3.27 | |||||
EV-to-EBITDA | 7.08 | |||||
EV-to-Forward-EBITDA | 3.27 | |||||
EV-to-Revenue | 4.14 | |||||
EV-to-Forward-Revenue | 2.62 | |||||
EV-to-FCF | 22.34 | |||||
Price-to-GF-Value | 0.57 | |||||
Price-to-Projected-FCF | 0.67 | |||||
Price-to-Median-PS-Value | 0.45 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.82 | |||||
Price-to-Graham-Number | 1.29 | |||||
| Price-to-Net-Current-Asset-Value | 1.78 | |||||
| Price-to-Net-Cash | 1.87 | |||||
Earnings Yield (Greenblatt) % | 13.85 | |||||
FCF Yield % | 2 | |||||
Forward Rate of Return (Yacktman) % | 19.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PharmaEngine Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 963.829 | ||
| EPS (TTM) (NT$) | 2.93 | ||
| Beta | -0.8264 | ||
| 3-Year Sharpe Ratio | -0.35 | ||
| 3-Year Sortino Ratio | -0.55 | ||
| Volatility % | 21.67 | ||
| 14-Day RSI | 45.5 | ||
| 14-Day ATR (NT$) | 1.980131 | ||
| 20-Day SMA (NT$) | 64.125 | ||
| 12-1 Month Momentum % | -7.85 | ||
| 52-Week Range (NT$) | 53 - 74.4 | ||
| Shares Outstanding (Mil) | 143.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PharmaEngine Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PharmaEngine Inc Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| TWD 2.000000 Cash Dividend | 2026-08-17 | -- | ||
| TWD 6.000000 Cash Dividend | 2025-08-13 | 78.00 (+1.17%) | ||
| 1.19995:1 Stock Split | 2017-07-26 | 183.34 (-2.87%) | ||
| 1.19992:1 Stock Split | 2016-07-25 | 161.13 (-0.22%) |
Show
Entries
PharmaEngine Inc Frequently Asked Questions
What is PharmaEngine Inc(ROCO:4162)'s stock price today?
The current price of ROCO:4162 is NT$62.10. The 52 week high of ROCO:4162 is NT$74.40 and 52 week low is NT$53.00.
When is next earnings date of PharmaEngine Inc(ROCO:4162)?
The next earnings date of PharmaEngine Inc(ROCO:4162) is .
Does PharmaEngine Inc(ROCO:4162) pay dividends? If so, how much?
The Dividend Yield %  of PharmaEngine Inc(ROCO:4162) is 9.66% (As of Today), Highest Dividend Payout Ratio of PharmaEngine Inc(ROCO:4162) was 3.45. The lowest was 0.12. And the median was 0.96. The  Forward Dividend Yield % of PharmaEngine Inc(ROCO:4162) is 3.22%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on PharmaEngine Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers